GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (NAS:GHRS) » Definitions » Valuation Rank

GHRS (GH Research) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is GH Research Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

GH Research Valuation Rank Related Terms

Thank you for viewing the detailed overview of GH Research's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

GH Research Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (NAS:GHRS) » Definitions » Valuation Rank
Comparable Companies
SNDX IMNM QURE AVBP XERS COGT AVXL REPL MENS VIR VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
1KA:Germany
Address
Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95
Website
https://www.ghres.com
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.